Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694217 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL10845203 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL9533237 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL1532527 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL8440104 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL14673470 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL1270067 | 0.98 | — | — | |
| SCHEMBL408956 | 0.90 | — | — | |
| Phosphine SCHEMBL10880551 | 0.88 | — | — | |
| SCHEMBL4441760 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4005126-A | Preparation of haloalkyl esters | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1977-01-25 | — | — | US | claimed |
| US-4005125-A | Preparation of haloalkyl esters | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1977-01-25 | — | — | US | claimed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200316090-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2020-10-08 | — | — | US | disclosed |
| US-10722525-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10675360-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10232049-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170128580-A1 | TARGETED THERAPEUTICS | TARVEDA THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-4005125-A | Preparation of haloalkyl esters | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-4005126-A | Preparation of haloalkyl esters | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-3989749-A | RENAL VASODILATORS, ANTITHROMBUS | MERCK & CO., INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3987091-A | RENAL VASODILATORS | MERCK & CO., INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3966773-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3950406-A | BRONCHODILATORS, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-04-13 | — | — | US | disclosed |
| US-3932479-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932463-A | BRONCHODILATORS, GASTRIC ACID SECRETION INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932472-A | INHIBITORS OF GASTRIC ACID SECRETION | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316090-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
| US-20170128580-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
| US-10675360-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
| US-10232049-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
| US-10722525-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | ALDH1A1 3249/4885LMNA 3127/4885APOBEC3A 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.